JPC-3210

JPC-3210 is an orally active aminomethylphenol. JPC-3210 exhibits anti-malarial activity with a mean IC50 ranging from 2.5 to 19 nM. JPC-3210 works by inhibiting the hemoglobin digestion pathway and promoting regulators of protein translation. JPC-3210 can inhibit CYP2D6 and CYP3A4 isozymes. JPC-3210 suppresses P. berghei infection in mice model. JPC-3210 possesses prophylactic protection in vivo. JPC-3210 can be studied in research on malaria prevention[1][2][3].

Product Specifications

CAS Number

[1609655-35-7]

UNSPSC

12352005

Target

Parasite

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Smiles

OC1=C(C2=CC(F)=C(C(F)(F)F)N=C2)C=C(C(C)(C)C)C=C1CNC(C)(C)C

Molecular Formula

C21H26F4N2O

Molecular Weight

398.44

References & Citations

[1]Birrell, G. W., et al., (2020) . Multi-omic Characterization of the Mode of Action of a Potent New Antimalarial Compound, JPC-3210, Against Plasmodium falciparum. Molecular & cellular proteomics : MCP, 19 (2), 308-325. |[2]Birrell, G. W., et al., (2018) . Characterization of the Preclinical Pharmacology of the New 2-Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention. Antimicrobial agents and chemotherapy, 62 (4), e01335-17. |[3]Chavchich, M., et al., (2016) . Lead Selection of a New Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention. Antimicrobial agents and chemotherapy, 60 (5), 3115-3118.